• Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery

    10 days ago - By Xconomy

    Insilico Medicine on Tuesday announced that it has entered a research collaboration with Pfizer, which Insilico CEO Alex Zhavoronkov says has “one of the most advanced AI teams internally both in target identification and chemistry.” Under the agreement, Pfizer will use Insilico's machine learning technology and proprietary Pandomics Discovery Platform. Pfizer, not new to applying such advanced analytics, also has worked with IBM Watson and Concerto HealthAI. “We will use our generative biology platform to attempt the discovery of new previously invisible biological targets implicated in...
    Read more ...